The study is a global phase-3 randomized study, with a double-blind treatment period of 8 weeks.

A study to evaluate the effectiveness and safety of TAK-491 and Chlorthalidone combined in one tablet (40/12.5 and 40/25 mg) in patients with high blood pressure who do not achieve target blood pressure on treatment with TAK-491 40 mg alone”

Registry ID

EUCTR2011-000220-16

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

TAKEDA EUROPE RESEARCH & DEVELOPMENT CENTRE LTD

Start date

2011-10-10

Last update

2026-08-16

Conditions

• Essential Hypertension
• Essential Hypertension Hipertensión Esencial

Summary

To evaluate the efficacy and safety of the fixed dose combinations of TAK-491 plus chlorthalidone (40/12.5 mg and 40/25 mg) in subjects with grades 2 or 3 essential hypertension who do not reach target blood pressure following 4 weeks of treatment with TAK-491 40 mg monotherapy.

Locations

• , , Germany
• , , Netherlands
• , , Estonia
• , , Slovakia
• , , Sweden
• , , Spain
• , , UK
• , , Poland
• , , Lithuania
• , , Hungary
• , , Italy

Related clinical trials

• Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension
• Childhood-Onset Essential Hypertension Natural History Study
• Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers
• Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
• To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
• Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN（FIM）

View on source registry